Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Cerebrospinal fluid from 70 patients with Alzheimer's disease (AD) and 96 patients with non‐AD neurological diseases as well as 19 normal control subjects was surveyed by sandwich enzyme‐linked immunosorbent assay to quantitate levels of the microtubule‐associated protein tau in cerebrospinal fluid. The tau level was significantly increased in AD patients as compared with that in patients with non‐AD neurological diseases and control subjects. Increased tau levels were found irrespective of age at onset, apolipoprotein E genotype, and clinical stage. Western blots of AD cerebrospinal fluid proteins revealed two to three tau‐immunoreactive bands with an apparent molecular mass between 50 and 65 kd consistent with phosphorylated cerebrospinal fluid tau. Taken together, our results suggest that cerebrospinal fluid tau might reflect the progressive accumulation of altered tau due to the progressive death of neurons in the AD brain, and that the enzyme‐linked immunosorbent assay of cerebrospinal fluid tau may prove to be a reliable and early diagnostic test for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Self-citationApolipoprotein E genotyping by one-stage PCR
Wenham, P., Price, W., & Blundell, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)92823-k · Cited by 1,069
Tau protein and the neurofibrillary pathology of Alzheimer's disease
Goedert, M. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90078-z · Cited by 716
Neural mechanisms of form and motion processing in the primate visual system
Van Essen, D. C., & Gallant, J. L. (1994) · Neuron · doi:10.1016/0896-6273(94)90455-3 · Cited by 606
A Neuronal Antigen in the Brains of Alzheimer Patients
Wolozin, B. L., Pruchnicki, A., Dickson, D. W., & Davies, P. (1986) · Science · doi:10.1126/science.3083509 · Cited by 585
Matsuo, E. S., Shin, R.-W., Billingsley, M. L., Van deVoorde, A., O'Connor, M., Trojanowski, J. Q., & Lee, V. M. Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 576
Self-citationHydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau.
Greenberg, S. G., Davies, P., Schein, J. D., & Binder, L. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48531-6 · Cited by 543
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Van de Voorde, A., Martin, J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 495
Cited by
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
“37 39 In AD, increased tau in the CSF is thought to occur as a direct result of tau accumulation in neurons, particularly axons; this disrupts neuronal activity and causes release into the extracellular space of cytoskeletal elements, including tau, which then appear in the CSF.40,41 Increased CSF tau correlates with…”
Self-citationBuée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,015
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Tau protein and the neurofibrillary pathology of Alzheimer's disease
Goedert, M. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90078-z · Cited by 716
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Praticò, D., Clark, C. M., Liun, F., Lee, V. Y.-M., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 584
Self-citationCerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citationSjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
“The first study in which t-tau could be successfully analyzed in CSF was published in 1995 and showed that the t-tau concentration was significantly elevated in AD patients compared with controls as well as in patients with other neurodegenerative disorders (Arai et al., 1995; Blennow et al., 1995).”
ResultSelf-citationPratic�, D., Clark, C. M., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & FitzGerald, G. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<809::aid-ana19>3.0.co;2-9 · Cited by 348
Self-citationElevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 341
Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Self-citationDecreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., Nellgård, P., Rosengren, L., Blennow, K., & Nellgård, B. (2006) · Neurology · doi:10.1212/01.wnl.0000242732.06714.0f · Cited by 321
Mechanisms of secretion and spreading of pathological tau protein
Brunello, C. A., Merezhko, M., Uronen, R.-L., & Huttunen, H. J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03349-1 · Cited by 304
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz–Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons
Ruan, Z., Pathak, D., Venkatesan Kalavai, S., Yoshii-Kitahara, A., Muraoka, S., Bhatt, N., Takamatsu-Yukawa, K., Hu, J., Wang, Y., Hersh, S., et al. (2021) · Brain · doi:10.1093/brain/awaa376 · Cited by 283
Buerger, K., Zinkowski, R., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann-Kiefer, K., DeBernardis, J., Kerkman, D., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 277
Self-citationShaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
“[61] Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, et al.”
BackgroundMechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review
Gibbons, G. S., Lee, V. M. Y., & Trojanowski, J. Q. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2505 · Cited by 257
Self-citationItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256
“01) as described previously.(4,6) As shown in Figure 1A, the CSF/total-tau levels were significantly increased in the AD group (p , 0.”
MethodSelf-citationBoth total and phosphorylated tau are increased in Alzheimer's disease
Sjogren, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 253
Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 221
MRI and CSF studies in the early diagnosis of Alzheimer's disease
De Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., Clark, C., Kerkman, D., DeBernardis, J., Li, J., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01381.x · Cited by 218
Self-citationMouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
“Common AD biomarkers include Aβ and tau levels in the CSF (Arai et al., 1995; Motter et al., 1995; Kanai et al., 1998).”
BackgroundInfluentialAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies
Higuchi, M., Tashiro, M., Arai, H., Okamura, N., Hara, S., Higuchi, S., Itoh, M., Shin, R.-W., Trojanowski, J. Q., & Sasaki, H. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7342 · Cited by 206
Self-citationCytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181
Park, J.-C., Han, S.-H., Yi, D., Byun, M. S., Lee, J. H., Jang, S., Ko, K., Jeon, S. Y., Lee, Y.-S., Kim, Y. K., et al. (2019) · Brain · doi:10.1093/brain/awy347 · Cited by 178
“It has long been discussed that CSF t-tau and p-tau levels increased during Alzheimer’s disease pathogenesis (Arai et al., 1995; Andreasen et al., 2001; Pereira et al., 2017) and that the tau/amyloid-b1–42 ratio in CSF is known to have good ability in distinguishing Alzheimer’s disease patients from normal subjects or…”
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P.-J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · cclm · doi:10.1515/cclm.2011.086 · Cited by 167
Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H., Morikawa, Y.-I., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., Machida, N., Lee, V. M.-Y., Trojanowski, J. Q., & Sasaki, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6908 · Cited by 159
Self-citationUrakami, K., Wada, K., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ishizu, H., Kashihara, K., Yamamoto, M., Tsuchiya-Ikemoto, K., et al. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00480-9 · Cited by 97
Self-citationSchiera, G., Di Liegro, C. M., & Di Liegro, I. (2015) · BioMed Research International · doi:10.1155/2015/152926 · Cited by 70
CSF tau and β-amyloid as biomarkers for mild cognitive impairment
Hampel, H., & Blennow, K. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/hhampel · Cited by 52
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48
Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease
Iwatsubo, T. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00015-3 · Cited by 37
Metadata
- Authors
- Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C. M., Lee, V. M. ‐., Trojanowski, J. Q., & Sasaki, H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1995-10
- Volume
- 38
- Issue
- 4
- Pages
- 649-652
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2022423664
- Cited by
- 298
- References
- 18
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.